Health Care • Biotechnology: Pharmaceutical Preparations
$10.23 ▼ -0.29
(-2.76%)
MKT CAP: $860.6M • VOL: 852.7K
52W L $6 52W H $27
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
CRVS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$43.0M | -$27.5M | -$23.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$15.3M | -$62.3M | -$27.0M |
| EBITDA (Normalized) | -$42.8M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$32.8M | -$25.4M | -$23.9M |
| Capital Expenditures (CapEx) | $174.0K | — | — |
| Free Cash Flow (FCF) | -$33.0M | -$25.4M | -$23.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.6M | $8.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $61.2M | $32.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRVS.